• Ironwood Pharmaceuticals Inc., of Cambridge, Mass., said second-quarter net sales of Linzess (linaclotide), as reported by partner Forest Laboratories Inc., of New York, were $28.8 million. More than 125,000 Linzess prescriptions were filled in the second quarter, with more than 200,000 prescriptions filled since the drug launched in December 2012, according to Ironwood. In addition, Ironwood's European partner, Almirall SA, of Barcelona, Spain, launched Constella (linaclotide) in the UK, Germany and the Nordic countries. The product is expected to launch in additional European countries throughout the remainder of 2013 and 2014. Ironwood reported second-quarter revenues of approximately $9.7 million, consisting of $6.1 million in sales of active pharmaceutical ingredient, $1.7 million in the amortization of deferred revenue associated with partnerships and $1.9 million in milestone payments from Almirall. Operating expenses were approximately $55 million. The company ended the quarter with approximately $301 million in cash, equivalents and marketable securities.